Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ladislav Pecen

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
BMJ Open|April 1, 2019
Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)Miklos Rohla, Thomas W Weiss, Ladislav Pecen, et al.
Archives of Cardiovascular Diseases|September 25, 2017
Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudyRaffaele De Caterina, Bernd Brüggenjürgen, Harald Darius, et al.
Circulation Reports|March 11, 2024
Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation Patients From Asia - One-Year Data From the Global ETNA-AF ProgramJong-Il Choi, Songsak Kiatchoosakun, Panyapat Jiampo, et al.
Anticancer Research|October 4, 2011
Vitamin D in colorectal, breast, prostate and lung cancer: a pilot studyPetr Pazdiora, Sarka Svobodova, Radka Fuchsova, et al.
JACC. Advances|June 28, 2024
Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe RegistryMarianne Gwechenberger, Gonzalo Barón-Esquivias, Tim A C de Vries, et al.
International Journal of Cardiology|May 1, 2018
Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudyJolanta M Siller-Matula, Ladislav Pecen, Giuseppe Patti, et al.
Journal for Immunotherapy of Cancer|December 12, 2018
Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patientsIva Truxova, Lenka Kasikova, Michal Hensler, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|July 26, 2022
Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical carePaulus Kirchhof, Ladislav Pecen, Ameet Bakhai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2019
TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian CancerJitka Fucikova, Jana Rakova, Michal Hensler, et al.
Journal for Immunotherapy of Cancer|August 22, 2020
M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancerMichal Hensler, Lenka Kasikova, Karel Fiser, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
BMJ Open|April 1, 2019
Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)Miklos Rohla, Thomas W Weiss, Ladislav Pecen, et al.
Archives of Cardiovascular Diseases|September 25, 2017
Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudyRaffaele De Caterina, Bernd Brüggenjürgen, Harald Darius, et al.
Circulation Reports|March 11, 2024
Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation Patients From Asia - One-Year Data From the Global ETNA-AF ProgramJong-Il Choi, Songsak Kiatchoosakun, Panyapat Jiampo, et al.
Anticancer Research|October 4, 2011
Vitamin D in colorectal, breast, prostate and lung cancer: a pilot studyPetr Pazdiora, Sarka Svobodova, Radka Fuchsova, et al.
JACC. Advances|June 28, 2024
Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe RegistryMarianne Gwechenberger, Gonzalo Barón-Esquivias, Tim A C de Vries, et al.
International Journal of Cardiology|May 1, 2018
Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudyJolanta M Siller-Matula, Ladislav Pecen, Giuseppe Patti, et al.
Journal for Immunotherapy of Cancer|December 12, 2018
Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patientsIva Truxova, Lenka Kasikova, Michal Hensler, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|July 26, 2022
Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical carePaulus Kirchhof, Ladislav Pecen, Ameet Bakhai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2019
TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian CancerJitka Fucikova, Jana Rakova, Michal Hensler, et al.
Journal for Immunotherapy of Cancer|August 22, 2020
M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancerMichal Hensler, Lenka Kasikova, Karel Fiser, et al.
Pageof 9